Performance of candidate urinary biomarkers for pancreatic cancer - Correlation with pancreatic cyst malignant progression?

Michele Yip-Schneider, Mazhar Soufi, Rosalie A. Carr, Katelyn F. Flick, Huangbing Wu, Cameron L. Colgate, C. Schmidt

Research output: Contribution to journalArticle

Abstract

Background: Intraductal papillary mucinous neoplasms (IPMN) are precursors of pancreatic cancer. Potential biomarkers of IPMN progression have not been identified in urine. A few urinary biomarkers were reported to be predictive of pancreatic ductal adenocarcinoma (PDAC). Here, we seek to assess their ability to detect high-risk IPMN. Methods: Urine was collected from patients undergoing pancreatic resection and healthy controls. TIMP-1(Tissue Inhibitor of Metalloproteinase-1), LYVE-1(Lymphatic Vessel Endothelial Receptor 1), and PGEM(Prostaglandin E Metabolite) levels were determined by ELISA and analyzed by Kruskal-Wallis. Results: Median urinary TIMP-1 levels were significantly lower in healthy controls (n = 9; 0.32 ng/mg creatinine) compared to PDAC (n = 13; 1.95) but not significantly different between low/moderate-grade (n = 20; 0.71) and high-grade/invasive IPMN (n = 20; 1.12). No significant difference in urinary LYVE-1 was detected between IPMN low/moderate (n = 16; 0.37 ng/mg creatinine) and high/invasive grades (n = 21; 0.09). Urinary PGEM levels were not significantly different between groups. Conclusions: Urinary TIMP-1, LYVE-1, and PGEM do not correlate with malignant potential of pancreatic cysts.

Original languageEnglish (US)
JournalAmerican Journal of Surgery
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Pancreatic Cyst
Pancreatic Neoplasms
Biomarkers
Tissue Inhibitor of Metalloproteinase-1
Lymphatic Vessels
Receptors, Prostaglandin E, EP1 Subtype
Neoplasms
Creatinine
Adenocarcinoma
Urine
Prostaglandins E
Enzyme-Linked Immunosorbent Assay

Keywords

  • Biomarker
  • Dysplasia
  • Intraductal papillary mucinous neoplasm
  • Pancreatic cancer
  • Pancreatic cyst
  • Urine

ASJC Scopus subject areas

  • Surgery

Cite this

Performance of candidate urinary biomarkers for pancreatic cancer - Correlation with pancreatic cyst malignant progression? / Yip-Schneider, Michele; Soufi, Mazhar; Carr, Rosalie A.; Flick, Katelyn F.; Wu, Huangbing; Colgate, Cameron L.; Schmidt, C.

In: American Journal of Surgery, 01.01.2019.

Research output: Contribution to journalArticle

@article{55d2a13e44f3450e9c972861129779d7,
title = "Performance of candidate urinary biomarkers for pancreatic cancer - Correlation with pancreatic cyst malignant progression?",
abstract = "Background: Intraductal papillary mucinous neoplasms (IPMN) are precursors of pancreatic cancer. Potential biomarkers of IPMN progression have not been identified in urine. A few urinary biomarkers were reported to be predictive of pancreatic ductal adenocarcinoma (PDAC). Here, we seek to assess their ability to detect high-risk IPMN. Methods: Urine was collected from patients undergoing pancreatic resection and healthy controls. TIMP-1(Tissue Inhibitor of Metalloproteinase-1), LYVE-1(Lymphatic Vessel Endothelial Receptor 1), and PGEM(Prostaglandin E Metabolite) levels were determined by ELISA and analyzed by Kruskal-Wallis. Results: Median urinary TIMP-1 levels were significantly lower in healthy controls (n = 9; 0.32 ng/mg creatinine) compared to PDAC (n = 13; 1.95) but not significantly different between low/moderate-grade (n = 20; 0.71) and high-grade/invasive IPMN (n = 20; 1.12). No significant difference in urinary LYVE-1 was detected between IPMN low/moderate (n = 16; 0.37 ng/mg creatinine) and high/invasive grades (n = 21; 0.09). Urinary PGEM levels were not significantly different between groups. Conclusions: Urinary TIMP-1, LYVE-1, and PGEM do not correlate with malignant potential of pancreatic cysts.",
keywords = "Biomarker, Dysplasia, Intraductal papillary mucinous neoplasm, Pancreatic cancer, Pancreatic cyst, Urine",
author = "Michele Yip-Schneider and Mazhar Soufi and Carr, {Rosalie A.} and Flick, {Katelyn F.} and Huangbing Wu and Colgate, {Cameron L.} and C. Schmidt",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.amjsurg.2019.09.013",
language = "English (US)",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Performance of candidate urinary biomarkers for pancreatic cancer - Correlation with pancreatic cyst malignant progression?

AU - Yip-Schneider, Michele

AU - Soufi, Mazhar

AU - Carr, Rosalie A.

AU - Flick, Katelyn F.

AU - Wu, Huangbing

AU - Colgate, Cameron L.

AU - Schmidt, C.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Intraductal papillary mucinous neoplasms (IPMN) are precursors of pancreatic cancer. Potential biomarkers of IPMN progression have not been identified in urine. A few urinary biomarkers were reported to be predictive of pancreatic ductal adenocarcinoma (PDAC). Here, we seek to assess their ability to detect high-risk IPMN. Methods: Urine was collected from patients undergoing pancreatic resection and healthy controls. TIMP-1(Tissue Inhibitor of Metalloproteinase-1), LYVE-1(Lymphatic Vessel Endothelial Receptor 1), and PGEM(Prostaglandin E Metabolite) levels were determined by ELISA and analyzed by Kruskal-Wallis. Results: Median urinary TIMP-1 levels were significantly lower in healthy controls (n = 9; 0.32 ng/mg creatinine) compared to PDAC (n = 13; 1.95) but not significantly different between low/moderate-grade (n = 20; 0.71) and high-grade/invasive IPMN (n = 20; 1.12). No significant difference in urinary LYVE-1 was detected between IPMN low/moderate (n = 16; 0.37 ng/mg creatinine) and high/invasive grades (n = 21; 0.09). Urinary PGEM levels were not significantly different between groups. Conclusions: Urinary TIMP-1, LYVE-1, and PGEM do not correlate with malignant potential of pancreatic cysts.

AB - Background: Intraductal papillary mucinous neoplasms (IPMN) are precursors of pancreatic cancer. Potential biomarkers of IPMN progression have not been identified in urine. A few urinary biomarkers were reported to be predictive of pancreatic ductal adenocarcinoma (PDAC). Here, we seek to assess their ability to detect high-risk IPMN. Methods: Urine was collected from patients undergoing pancreatic resection and healthy controls. TIMP-1(Tissue Inhibitor of Metalloproteinase-1), LYVE-1(Lymphatic Vessel Endothelial Receptor 1), and PGEM(Prostaglandin E Metabolite) levels were determined by ELISA and analyzed by Kruskal-Wallis. Results: Median urinary TIMP-1 levels were significantly lower in healthy controls (n = 9; 0.32 ng/mg creatinine) compared to PDAC (n = 13; 1.95) but not significantly different between low/moderate-grade (n = 20; 0.71) and high-grade/invasive IPMN (n = 20; 1.12). No significant difference in urinary LYVE-1 was detected between IPMN low/moderate (n = 16; 0.37 ng/mg creatinine) and high/invasive grades (n = 21; 0.09). Urinary PGEM levels were not significantly different between groups. Conclusions: Urinary TIMP-1, LYVE-1, and PGEM do not correlate with malignant potential of pancreatic cysts.

KW - Biomarker

KW - Dysplasia

KW - Intraductal papillary mucinous neoplasm

KW - Pancreatic cancer

KW - Pancreatic cyst

KW - Urine

UR - http://www.scopus.com/inward/record.url?scp=85072320936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072320936&partnerID=8YFLogxK

U2 - 10.1016/j.amjsurg.2019.09.013

DO - 10.1016/j.amjsurg.2019.09.013

M3 - Article

AN - SCOPUS:85072320936

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

ER -